Toxic epidermal necrolysis associated with pembrolizumab.

Cai, Zhuo Ran; Lecours, Julie; Adam, Jean-Philippe; Marcil, Isabelle; Blais, Normand; Dallaire, Mario; Belisle, Annie; Mathieu, Alexandre

doi:10.1177/1078155219890659

Record: found
Abstract: found
Article: not found

Toxic epidermal necrolysis associated with pembrolizumab.

Author(s): Zhuo Ran Cai ¹ , Julie Lecours ¹ , Jean-Philippe Adam ² ^, ³ , Isabelle Marcil ¹ , Normand Blais ³ ^, ⁴ , Mario Dallaire ⁵ , Annie Belisle ⁶ , Alexandre Mathieu ² ^, ³

Publication date (Electronic): Jul 2020

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Publisher: SAGE Publications

Keywords: Adverse reaction, immune-related adverse events, immunotherapy, pembrolizumab, toxic epidermal necrolysis

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Stevens-Johnson syndrome and toxic epidermal necrolysis are severe cutaneous drug eruptions characterized by epidermal detachment. Pembrolizumab is a monoclonal antibody that binds to the programmed death-1 receptor, and it has been associated with numerous cutaneous adverse side-effects, including Stevens-Johnson syndrome.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Oncol Pharm Pract

Title: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Publisher: SAGE Publications

ISSN (Electronic): 1477-092X

ISSN (Print): 1078-1552

Publication date (Electronic): Jul 2020

Volume: 26

Issue: 5

Affiliations

[1 ] Department of Dermatology, Centre Hospitalier de l'Université de Montréal, Québec, Canada.

[2 ] Department of Pharmacy, Centre Hospitalier de l'Université de Montréal, Québec, Canada.

[3 ] Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada.

[4 ] Department of Medicine, Service of Hematology, Oncology and Blood Bank, Centre Hospitalier de l'Université de Montréal, Québec, Canada.

[5 ] Department of Medicine, Centre intégré de santé et des services sociaux de l'Outaouais, Québec, Canada.

[6 ] Department of Pathology, Centre Hospitalier de l'Université de Montréal, Québec, Canada.

Article

DOI: 10.1177/1078155219890659

PubMed ID: 31810421

SO-VID: 14c0268b-3864-4b7f-a20c-db54b25d5f27

History

Keywords: pembrolizumab,immunotherapy,immune-related adverse events,Adverse reaction,toxic epidermal necrolysis

Data availability:

Keywords: pembrolizumab, immunotherapy, immune-related adverse events, Adverse reaction, toxic epidermal necrolysis

Toxic epidermal necrolysis associated with pembrolizumab.

Read this article at

Abstract

Related collections

Cancer Immunotherapy

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 280

Cited by 12